RU2684616C2 - Стероидное соединение для применения в лечении печеночной энцефалопатии - Google Patents
Стероидное соединение для применения в лечении печеночной энцефалопатии Download PDFInfo
- Publication number
- RU2684616C2 RU2684616C2 RU2016127558A RU2016127558A RU2684616C2 RU 2684616 C2 RU2684616 C2 RU 2684616C2 RU 2016127558 A RU2016127558 A RU 2016127558A RU 2016127558 A RU2016127558 A RU 2016127558A RU 2684616 C2 RU2684616 C2 RU 2684616C2
- Authority
- RU
- Russia
- Prior art keywords
- hepatic encephalopathy
- hydroxyandrostan
- rats
- ethynyl
- oxime
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450089 | 2014-01-29 | ||
| SE1450089-6 | 2014-01-29 | ||
| PCT/GB2015/050060 WO2015114308A1 (en) | 2014-01-29 | 2015-01-14 | Steroid compound for use in the treatment of hepatic encephalopathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016127558A RU2016127558A (ru) | 2018-03-05 |
| RU2016127558A3 RU2016127558A3 (cg-RX-API-DMAC10.html) | 2018-09-27 |
| RU2684616C2 true RU2684616C2 (ru) | 2019-04-10 |
Family
ID=52544513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016127558A RU2684616C2 (ru) | 2014-01-29 | 2015-01-14 | Стероидное соединение для применения в лечении печеночной энцефалопатии |
Country Status (25)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106163528A (zh) | 2014-01-29 | 2016-11-23 | 梅克芳识别有限公司 | 用于治疗肝脑病的甾族化合物 |
| TWI748936B (zh) | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ａｂ公司 | 新穎化合物 |
| US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
| WO2019053578A1 (en) | 2017-09-12 | 2019-03-21 | Eth Zurich | TRANSMEMBRANE PH GRADIENT POLYMERSOMES FOR THE QUANTIFICATION OF AMMONIA IN BODY FLUIDS |
| UA128186C2 (uk) * | 2017-11-27 | 2024-05-01 | Умекрайн Когнішн Аб | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 3<font face="Symbol">a</font>-ЕТИНІЛ-3<font face="Symbol">b</font>-ГІДРОКСІАНДРОСТАН-17-ОНУ ОКСИМУ |
| EP4079307A1 (en) * | 2021-04-20 | 2022-10-26 | Umecrine Cognition AB | New medical use |
| US20230134958A1 (en) * | 2021-10-29 | 2023-05-04 | Umecrine Cognition Ab | New medical treatment |
| EP4389129A1 (en) * | 2022-12-22 | 2024-06-26 | Umecrine Cognition AB | 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia |
| WO2025252725A1 (en) | 2024-06-04 | 2025-12-11 | Umecrine Cognition Ab | Novel pharmaceutical formulation of golexanolone |
| WO2025252724A1 (en) | 2024-06-04 | 2025-12-11 | Umecrine Cognition Ab | Novel pharmaceutical formulation of golexanolone |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007103162A2 (en) * | 2006-03-01 | 2007-09-13 | Samaritan Pharmaceuticals, Inc. | Structure based drug design of steroidogenesis inhibitors |
| WO2008063128A1 (en) * | 2006-11-21 | 2008-05-29 | Umecrine Ab | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
| RU2358733C2 (ru) * | 2001-12-06 | 2009-06-20 | ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО.,ЛТД. | Фармацевтические композиции и их применения |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2713061A (en) | 1951-04-06 | 1955-07-12 | Schering Ag | 3-methyl androstanes |
| FR1463755A (fr) | 1960-01-26 | 1966-07-22 | Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation | |
| US3173932A (en) | 1962-11-02 | 1965-03-16 | American Cyanamid Co | 15-substituted estra-1, 3, 5(10)-trienes |
| FR2685332A1 (fr) | 1991-12-20 | 1993-06-25 | Roussel Uclaf | Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments. |
| JP4008024B2 (ja) | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| CN1270718C (zh) | 1998-03-11 | 2006-08-23 | 托布乔恩·贝克斯托罗姆 | 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用 |
| US6593321B2 (en) | 2001-06-11 | 2003-07-15 | Southwest Foundation For Biomedical Research | 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity |
| SE0104423D0 (sv) * | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
| PT2319581E (pt) | 2004-11-26 | 2015-06-30 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| BRPI0920465A2 (pt) * | 2008-10-02 | 2018-03-20 | Salix Pharmaceuticals, Inc. | metodo de tratamento de encefalopatia hepática |
| ES2517340T3 (es) | 2009-06-08 | 2014-11-03 | Ucl Business Plc | Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato |
| EP3019074B1 (en) | 2013-09-30 | 2018-08-29 | Horizon Therapeutics, LLC | Diagnosing, grading, monitoring, and treating hepatic encephalopathy |
| CN106163528A (zh) | 2014-01-29 | 2016-11-23 | 梅克芳识别有限公司 | 用于治疗肝脑病的甾族化合物 |
-
2015
- 2015-01-14 CN CN201580006600.1A patent/CN106163528A/zh active Pending
- 2015-01-14 EP EP15705691.2A patent/EP3099306B1/en active Active
- 2015-01-14 DK DK15705691.2T patent/DK3099306T3/en active
- 2015-01-14 CN CN202110480203.5A patent/CN113185566A/zh active Pending
- 2015-01-14 BR BR112016017620A patent/BR112016017620A2/pt not_active Application Discontinuation
- 2015-01-14 PT PT15705691T patent/PT3099306T/pt unknown
- 2015-01-14 JP JP2016544557A patent/JP6543633B2/ja active Active
- 2015-01-14 SI SI201530591T patent/SI3099306T1/sl unknown
- 2015-01-14 ME MEP-2019-39A patent/ME03351B/me unknown
- 2015-01-14 MX MX2016008851A patent/MX2016008851A/es active IP Right Grant
- 2015-01-14 AU AU2015212606A patent/AU2015212606B2/en active Active
- 2015-01-14 TR TR2019/01687T patent/TR201901687T4/tr unknown
- 2015-01-14 WO PCT/GB2015/050060 patent/WO2015114308A1/en not_active Ceased
- 2015-01-14 SM SM20190133T patent/SMT201900133T1/it unknown
- 2015-01-14 LT LTEP15705691.2T patent/LT3099306T/lt unknown
- 2015-01-14 RS RS20190234A patent/RS58375B1/sr unknown
- 2015-01-14 CA CA2935015A patent/CA2935015C/en active Active
- 2015-01-14 PL PL15705691T patent/PL3099306T3/pl unknown
- 2015-01-14 US US15/114,972 patent/US20160339040A1/en not_active Abandoned
- 2015-01-14 RU RU2016127558A patent/RU2684616C2/ru active
- 2015-01-14 HU HUE15705691A patent/HUE042242T2/hu unknown
- 2015-01-14 KR KR1020167023426A patent/KR102324667B1/ko active Active
- 2015-01-14 ES ES15705691T patent/ES2714563T3/es active Active
- 2015-01-14 HR HRP20190251TT patent/HRP20190251T1/hr unknown
-
2016
- 2016-06-28 IL IL246496A patent/IL246496B/en active IP Right Grant
- 2016-11-15 US US15/352,035 patent/US9801894B2/en active Active
-
2017
- 2017-09-27 US US15/716,838 patent/US10342804B2/en active Active
-
2019
- 2019-03-12 CY CY20191100299T patent/CY1121464T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2358733C2 (ru) * | 2001-12-06 | 2009-06-20 | ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО.,ЛТД. | Фармацевтические композиции и их применения |
| WO2007103162A2 (en) * | 2006-03-01 | 2007-09-13 | Samaritan Pharmaceuticals, Inc. | Structure based drug design of steroidogenesis inhibitors |
| WO2008063128A1 (en) * | 2006-11-21 | 2008-05-29 | Umecrine Ab | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015212606B2 (en) | Steroid compound for use in the treatment of hepatic encephalopathy | |
| US11318113B2 (en) | Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production | |
| Erhardt et al. | Endogenous kynurenic acid disrupts prepulse inhibition | |
| Xiao et al. | Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat | |
| JP2017507113A5 (cg-RX-API-DMAC10.html) | ||
| KR20170095302A (ko) | 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물 | |
| Liu et al. | Stabilization of HIF-1α modulates VEGF and Caspase-3 in the hippocampus of rats following transient global ischemia induced by asphyxial cardiac arrest | |
| JP2023504194A (ja) | インスリン耐性における使用方法のための治療化合物 | |
| JP3973561B2 (ja) | カリウムチャネル開口薬 | |
| US20130004506A1 (en) | Method for treating pathologies associated with hypoxia using mif inhibitors | |
| US10653668B2 (en) | Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production | |
| HK1228753A1 (en) | Steroid compound for use in the treatment of hepatic encephalopathy | |
| HK1228753B (en) | Steroid compound for use in the treatment of hepatic encephalopathy | |
| NZ721622B2 (en) | Steroid compound for use in the treatment of hepatic encephalopathy | |
| US20210308138A1 (en) | Tissue transglutaminase modulators for medicinal use | |
| US12139505B2 (en) | Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same | |
| Schwieler | Endogenous Kynurenic Acid and Schizophrenia-Physiological and Pharmacological Aspects | |
| Strielkov et al. | Hypoxic Pulmonary Hypertension: Current Views on Pathogenesis and Pharmacological Treatment Options |